Suspension of trading
Exscientia plc Share Price
Stocks
EXAI
US30223G1022
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.840 USD | +3.20% |
|
-.--% | - |
| 20/11/24 | Exscientia plc(NasdaqGS:EXAI) dropped from S&P Global BMI Index | CI |
| 20/11/24 | Recursion Pharmaceuticals, Exscientia Complete Business Combination | MT |
| Market Cap | 500M 661M 576M 534M 936M 62.37B 943M 6.34B 2.45B 30.71B 2.48B 2.43B 107B | P/E 2022 |
-4.55x | P/E 2023 | -4.28x |
|---|---|---|---|---|---|
| Enterprise Value | 156M 206M 180M 166M 292M 19.43B 294M 1.97B 765M 9.57B 773M 757M 33.24B | EV / Sales 2022 |
1.9x | EV / Sales 2023 | 14.2x |
| Free-Float |
36.87% | Yield 2022 * |
-
| Yield 2023 | - |
| 1 day | +3.20% |
| 3 years | 3.8 |  | 9.12 |
| 5 years | 3.8 | | 30.38 |
| 10 years | 3.8 | | 30.38 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Tech/Sci/R&D Officer | - | 30/04/2022 | |
| Chief Tech/Sci/R&D Officer | 61 | 05/06/2024 | |
John Overington
CTO | Chief Tech/Sci/R&D Officer | - | 30/04/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Mario Polywka
BRD | Director/Board Member | 63 | 27/09/2017 |
Elizabeth Crain
CHM | Chairman | 61 | 11/02/2024 |
Robert Ghenchev
BRD | Director/Board Member | 43 | 30/04/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.20% | -.--% | -.--% | -32.31% | 633M | |
| +1.44% | +1.71% | -10.63% | -9.16% | 43.13B | |
| +3.31% | +5.93% | +308.19% | +562.02% | 34.65B | |
| +2.84% | +2.14% | +6.87% | +34.93% | 30.03B | |
| -1.70% | -7.54% | +8.51% | -22.34% | 28B | |
| -1.90% | -1.56% | +11.62% | +19.80% | 24.45B | |
| -0.14% | +5.86% | - | - | 14.34B | |
| +0.68% | -1.53% | +52.04% | +107.47% | 13.14B | |
| -0.57% | -2.43% | +5.18% | +4.20% | 12.53B | |
| -0.26% | +1.15% | +100.27% | +80.69% | 12.25B | |
| Average | +0.69% | +0.66% | +53.56% | +82.81% | 21.32B | |
| Weighted average by Cap. | +0.78% | +1.27% | +65.02% | +112.76% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | 27.22M 36.02M 31.4M 29.06M 50.99M 3.4B 51.37M 345M 134M 1.67B 135M 132M 5.81B | 20.08M 26.57M 23.16M 21.44M 37.61M 2.51B 37.89M 255M 98.6M 1.23B 99.63M 97.58M 4.29B |
| Net income | -119M -157M -137M -127M -222M -14.82B -224M -1.51B -583M -7.3B -589M -577M -25.34B | -146M -193M -168M -156M -273M -18.21B -275M -1.85B -717M -8.97B -724M -709M -31.16B |
| Net Debt | -492M -651M -567M -525M -921M -61.39B -928M -6.24B -2.42B -30.23B -2.44B -2.39B -105B | -344M -455M -397M -367M -645M -42.94B -649M -4.36B -1.69B -21.14B -1.71B -1.67B -73.46B |
Employees
483
- Stock Market
- Stocks
- EXAI Stock
Select your edition
All financial news and data tailored to specific country editions
